title: Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification.
abstract: 11q13 amplifications have been found in several cancers, including bladder tumours. However, the biological significance of this genetic alteration is not yet fully understood. To get more insight into the role of 11q13 amplification in bladder tumour development, we have studied the level of amplification and expression of 4 (protoonco)genes lying within the amplicon; cyclin D1, FGF3, FGF4 and EMS1 DNA amplification was found in 5/46 tumours. There was no correlation between amplification and clinico-pathological data. No expression of FGF3 and FGF4 was detected whereas both cyclin D1 and EMS1 were expressed at higher level in tumours with amplifications. Thus cyclin D1 and EMS1, but not FGF3 and FGF4, are likely to play a pathogenic role in the 11q13 amplification in bladder cancer. However, amplification is not the unique way of activation of these genes. Indeed, in situ hybridisation and Northern blot analysis have shown that most bladder tumours have a fair to high expression of cyclin D1 and EMS1 in contrast to normal urothelium with a moderate expression. Interestingly, a trend towards higher expression occurs in superficial versus invasive tumours (8.8 +/- 2.0 versus 1.9 +/- 0.4; P approximately equal to 13% for cyclin D1 and 4.5 +/- 1.4 versus 2.0 +/- 0.4; P approximately equal to 8% for EMS1). Moreover, the 9 tumours with low expression are all highly malignant, leading to the hypothesis that the tumours developing through a cyclin D1/EMS1 independent pathway are more aggressive.
authors.affiliation: Urological Research Laboratory, University Hospital Nijmegen, The Netherlands.
authors.forename: P P
authors.initials: PP
authors.lastname: Bringuier
authors.forename: Y
authors.initials: Y
authors.lastname: Tamimi
authors.forename: E
authors.initials: E
authors.lastname: Schuuring
authors.forename: J
authors.initials: J
authors.lastname: Schalken
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000235:genetics; D002880:Chromosomes, Human, Pair 11; D051356:Cortactin; D019938:Cyclin D1; D016213:Cyclins / Q000235:genetics*; D051519:Fibroblast Growth Factor 4; D005346:Fibroblast Growth Factors / Q000235:genetics*; D005784:Gene Amplification; D015870:Gene Expression; D006801:Humans; D008840:Microfilament Proteins; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009367:Neoplasm Staging; D015513:Oncogene Proteins / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D014158:Transcription, Genetic; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
chemical_list: C495868:CTTN protein, human; D051356:Cortactin; D016213:Cyclins; C496445:FGF4 protein, human; D051519:Fibroblast Growth Factor 4; D008840:Microfilament Proteins; D009363:Neoplasm Proteins; D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D019938:Cyclin D1; D005346:Fibroblast Growth Factors